SAN DIEGO, Dec. 2, 2013 /PRNewswire/ -- Organovo
Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional
biology company focused on delivering breakthrough 3D bioprinting
technology, has been invited to present at the 24th Annual
Oppenheimer Healthcare Conference, which will be held in
New York December 10-11, 2013.
Organovo's Chairman and Chief Executive Officer, Keith Murphy, will be presenting on Wednesday, December 11, at 2:45pm ET.
The objective of the Oppenheimer 24th Annual Healthcare
Conference is to provide investors a broad spectrum of public and
private healthcare companies spanning all major sectors of the
healthcare industry, including bio & specialty pharmaceuticals;
biotechnology; medical devices; healthcare facilities; life science
tools and diagnostics; healthcare information technology and
distribution, and healthcare providers and servicers. The
conference will be held at the Crowne Plaza Hotel – New York.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human
tissues for medical research and therapeutic applications. The
Company is collaborating with pharmaceutical and academic partners
to develop human biological disease models in three dimensions.
These 3D human tissues have the potential to accelerate the drug
discovery process, enabling treatments to be developed faster and
at lower cost. In addition to numerous scientific publications, the
Company's technology has been featured in The Wall Street Journal,
Time Magazine, The Economist, and numerous others. Organovo is
changing the shape of medical research and practice. Learn more at
www.organovo.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995. Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the Company's
products and technology; and the Company's business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors are
identified and described in more detail in our filings with the
SEC, including our report on Form 10-Q filed November 8, 2013, the prospectus supplement filed
with the SEC on August 2, 2013 and
the transition report on Form 10-KT filed with the SEC on
May 24, 2013 and our other filings
with the Securities and Exchange Commission. You should not place
undue reliance on these forward-looking statements, which speak
only as of the date that they were made. These cautionary
statements should be considered with any written or oral
forward-looking statements that we may issue in the future. Except
as required by applicable law, including the securities laws of
the United States, we do not
intend to update any of the forward-looking statements to conform
these statements to reflect actual results, later events or
circumstances or to reflect the occurrence of unanticipated
events.
SOURCE Organovo Holdings, Inc.
